AVROBIO, Inc. (AVRO)

NASDAQ: AVRO · IEX Real-Time Price · USD
0.891
-0.019 (-2.04%)
Feb 1, 2023, 10:07 AM EST - Market open
-2.04%
Market Cap 39.65M
Revenue (ttm) n/a
Net Income (ttm) -109.08M
Shares Out 43.77M
EPS (ttm) -2.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,644
Open 0.910
Previous Close 0.910
Day's Range 0.891 - 0.919
52-Week Range 0.560 - 1.980
Beta 1.69
Analysts Buy
Price Target 3.57 (+300.49%)
Earnings Date Mar 16, 2023

About AVRO

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of ty... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2018
Employees 122
Stock Exchange NASDAQ
Ticker Symbol AVRO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for AVRO stock is "Buy." The 12-month stock price forecast is $3.57, which is an increase of 300.49% from the latest price.

Price Target
$3.57
(300.49% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the com...

3 weeks ago - Business Wire

AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced new interim ...

2 months ago - Business Wire

AVROBIO to Share Comprehensive Gaucher Disease Program Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will...

2 months ago - Business Wire

AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported favor...

4 months ago - Business Wire

AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that...

4 months ago - Business Wire

AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that...

4 months ago - Business Wire

AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that...

5 months ago - Business Wire

AVROBIO to Participate in Four Upcoming Investor Conferences in September

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that...

5 months ago - Business Wire

AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported finan...

6 months ago - Business Wire

AVROBIO to Participate in Two Upcoming Investor Conferences in August

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today ...

6 months ago - Business Wire

AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today ...

7 months ago - Business Wire

AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study

Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different ...

9 months ago - Zacks Investment Research

AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced ...

9 months ago - Business Wire

AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study

AVROBIO Inc (NASDAQ: AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition characterized by the accumulation of the amino acid cy...

9 months ago - Benzinga

AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported n...

9 months ago - Business Wire

AVROBIO to Present at the H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today ...

9 months ago - Business Wire

AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported f...

9 months ago - Business Wire

AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced ...

9 months ago - Business Wire

AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced ...

10 months ago - Business Wire